Literature DB >> 22264762

Synthesis and in vitro evaluation of 68Ga-DOTA-4-FBn-TN14003, a novel tracer for the imaging of CXCR4 expression.

Ute Hennrich1, Lisa Seyler, Martin Schäfer, Ulrike Bauder-Wüst, Michael Eisenhut, Wolfhard Semmler, Tobias Bäuerle.   

Abstract

The expression of the chemokine receptor CXCR4 in tumors is associated with tumor aggressiveness and poor prognosis for the patient and contributes to metastatic seeding. Therefore it is of high interest to find a specific PET tracer for the imaging of CXCR4 expression in tumors. The aim of this study was the synthesis, (68)Ga labeling and first evaluation of DOTA-4-FBn-TN14003 as a potential PET tracer for this purpose. DOTA-4-FBn-TN14003 was synthesized using solid phase peptide synthesis and radiolabeling of this versatile precursor was performed with (68)Ga, which was obtained from a (68)Ge/(68)Ga generator. (68)Ga-DOTA-4-FBn-TN14003 was reproducibly obtained in isolated radiochemical yields of 72.5±4.9% with an excellent radiochemical purity of >99.5%. Specific activities of up to 29.8±3.1 GBq/μmol were achieved. In competition binding assays with SDF-1α, human T cell lymphoma Jurkat cells expressed high levels of CXCR4 whereas human breast cancer MDA-MB-231 cells expressed significantly lower levels of this chemokine receptor. The inhibition constants (IC(50)) of Ga-DOTA-4-FBn-TN14003 and 4-FBn-TN14003 to CXCR4 were determined in a competition assay against (125)I-SDF-1α using Jurkat as well as MDA-MB-231 cells. The IC(50) values of Ga-DOTA-4-FBn-TN14003 (1.99±0.31 nM) and 4-FBn-TN14003 (4.07±1.00 nM) proved to be comparable, indicating negligible influence of the metal complex. These results suggest (68)Ga-DOTA-4-FBn-TN14003 as a promising agent for the imaging of CXCR4 expression in tumors and metastases.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22264762     DOI: 10.1016/j.bmc.2011.12.052

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  10 in total

Review 1.  Multimodality imaging of CXCR4 in cancer: current status towards clinical translation.

Authors:  T R Nayak; H Hong; Y Zhang; W Cai
Journal:  Curr Mol Med       Date:  2013-12       Impact factor: 2.222

Review 2.  68Ga-DOTA and analogs: Current status and future perspectives.

Authors:  Krzysztof Kilian
Journal:  Rep Pract Oncol Radiother       Date:  2014-05-19

3.  A benzenesulfonamide derivative as a novel PET radioligand for CXCR4.

Authors:  Yoon Hyeun Oum; Dinesh Shetty; Younghyoun Yoon; Zhongxing Liang; Ronald J Voll; Mark M Goodman; Hyunsuk Shim
Journal:  Bioorg Med Chem       Date:  2019-11-30       Impact factor: 3.641

4.  Al[18F]NOTA-T140 Peptide for Noninvasive Visualization of CXCR4 Expression.

Authors:  Xuefeng Yan; Gang Niu; Zhe Wang; Xiangyu Yang; Dale O Kiesewetter; Orit Jacobson; Baozhong Shen; Xiaoyuan Chen
Journal:  Mol Imaging Biol       Date:  2016-02       Impact factor: 3.488

5.  Comparison of (18)F-labeled CXCR4 antagonist peptides for PET imaging of CXCR4 expression.

Authors:  Xiao-Xiang Zhang; Zhongchan Sun; Jinxia Guo; Zhe Wang; Chenxi Wu; Gang Niu; Ying Ma; Dale O Kiesewetter; Xiaoyuan Chen
Journal:  Mol Imaging Biol       Date:  2013-12       Impact factor: 3.488

Review 6.  Prospective of ⁶⁸Ga-radiopharmaceutical development.

Authors:  Irina Velikyan
Journal:  Theranostics       Date:  2013-12-10       Impact factor: 11.556

7.  Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging.

Authors:  Hans Jürgen Wester; Ulrich Keller; Margret Schottelius; Ambros Beer; Kathrin Philipp-Abbrederis; Frauke Hoffmann; Jakub Šimeček; Carlos Gerngross; Michael Lassmann; Ken Herrmann; Natalia Pellegata; Martina Rudelius; Horst Kessler; Markus Schwaiger
Journal:  Theranostics       Date:  2015-03-01       Impact factor: 11.556

Review 8.  Prospective of 68Ga Radionuclide Contribution to the Development of Imaging Agents for Infection and Inflammation.

Authors:  Irina Velikyan
Journal:  Contrast Media Mol Imaging       Date:  2018-01-04       Impact factor: 3.161

Review 9.  Molecular imaging of chemokine receptor CXCR4.

Authors:  Ido D Weiss; Orit Jacobson
Journal:  Theranostics       Date:  2013-01-15       Impact factor: 11.556

10.  Automated Synthesis of Fluorine-18 Labeled CXCR4 Ligand via the Conjugation with Nicotinic Acid N-Hydroxysuccinimide Ester (6-[18F]SFPy).

Authors:  Falguni Basuli; Xiang Zhang; Tim E Phelps; Elaine M Jagoda; Peter L Choyke; Rolf E Swenson
Journal:  Molecules       Date:  2020-08-27       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.